MarketPeel
Insider Trading Intelligence
CK

Christopher John Kenney

XENE
CHIEF MEDICAL OFFICER · XENON PHARMACEUTICALS INC. · CIK 0001880129
FILING MIX · LIFETIME71%/29%
BUYS
12
SELLS
5
TOTAL VALUE
$289.1K
COMPANIES
1
ACTIVE SINCE
Aug 2021
HOLDINGS NOW
7,069
AVG SELL PX
$55.10
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Christopher John Kenney, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+75.00%-1.68%+0.34%-2.02%-0.81%
14d4+75.00%-1.33%-0.49%-0.84%-0.12%
30d4+50.00%+8.81%+1.85%+6.96%+5.13%
60d4+75.00%+9.28%+7.00%+2.28%+1.43%
90d4+75.00%+4.99%+7.37%-2.38%-5.74%
180d4(2 pending)+50.00%+16.34%+1.22%+15.11%+15.11%
1y4(2 pending)+50.00%+32.92%+12.73%+20.19%+20.19%
2y4(2 pending)+50.00%+38.92%+31.46%+7.46%+7.46%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XENE · 7,069 shares · as of Mar 13, 2026
037,50075,000112,500150,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 12 buys / 5 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XENE
XENON PHARMACEUTICALS INC.
SALE10b5-1
10b5-1 plan
1,410$55.23$77.9K7,069Mar 13, 2026Mar 13, 2026View →
XENE
XENON PHARMACEUTICALS INC.
SALE
Chief Medical Officer
3,75011,250Mar 12, 2026Mar 13, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASE
Chief Medical Officer
3,7508,479Mar 12, 2026Mar 13, 2026View →
XENE
XENON PHARMACEUTICALS INC.
SALE10b5-1
10b5-1 plan
2,771$60.11$166.6K4,729Mar 10, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASE
Chief Medical Officer
7,5007,500Mar 9, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
7,5007,500Mar 9, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
SALE
Chief Medical Officer
7,5000Mar 9, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
100,000100,000Jan 9, 2026Jan 9, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
20,00020,000Jan 9, 2026Jan 9, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
80,00080,000Mar 12, 2025Mar 13, 2025View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
15,00015,000Mar 12, 2025Mar 13, 2025View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
100,000100,000Mar 11, 2024Mar 12, 2024View →
XENE
XENON PHARMACEUTICALS INC.
SALE
Chief Medical Officer
700$35.01$24.5K0Mar 24, 2023Mar 24, 2023View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
120,000120,000Mar 10, 2023Mar 14, 2023View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000125,000Mar 10, 2022Mar 14, 2022View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASE
Chief Medical Officer
700$28.81$20.2K700Jan 21, 2022Jan 21, 2022View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
150,000150,000Aug 23, 2021Aug 25, 2021View →
Other insiders · XENE
Loading peer insiders…
About this filer
CIK 0001880129
ROLE
Chief Medical Officer
PRIMARY
XENE
COMPANIES
1
ACTIVE SINCE
Aug 2021
MARKETPEEL · /INSIDER/0001880129DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback